Published in Cancer Weekly, February 2nd, 2010
"They received oxaliplatin 130 mg/m(2) as 2-hour intravenous infusion on day I and oral capecitabine 1000 mg/m(2) twice daily on days 1 to 14 every 3 weeks XELOX. All patients were assessable for toxicity and 41 patients for response. Median age was 75 years (range, 70-83). In total, 215 cycles of XELOX were delivered. The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.